Efficacy of intravenous vitamin-D selective receptor activator [Paricalcitol] in management of secondary Hyperparathyroidism in Hemodialysis patients, single center experience

ABSTRACT

Background: secondary hyperparathyroidism [SHPT], a complication of chronic kidney disease [CKD] and is characterized by not only increased serum levels of intact parathyroid hormone [iPTH], but also may cause skeletal and cardiovascular complications. Deficiency of calcitriol [1, 25-hydroxy vitamin D] caused by impaired renal function, a main factor in the pathogenesis and pathophysiology of secondary hyperparathyroidism [SHPT] is associated with poor outcomes in hemodialysis patients. Therapy with vitamin D receptor [VDR] activators, including calcitriol or the selective VDR activator paricalcitol, has been associated with improved survival in patients with CKD on hemodialysis